Fig. 3: Kaplan–Meier plots of overall survival (OS) and progression-free survival (PFS) in patients with mantle cell lymphoma treated with first-line therapy. | Blood Cancer Journal

Fig. 3: Kaplan–Meier plots of overall survival (OS) and progression-free survival (PFS) in patients with mantle cell lymphoma treated with first-line therapy.

From: Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

Fig. 3

a, b OS and PFS for patients with or without upfront stem cell transplantation (SCT) as consolidation. c, d OS and PFS for patients older or younger than 65 years when first-line treatment was commenced. Patients older than 65 years had an inferior median OS (67.6 months; 95% CI, 57.1–85.0 months versus 158.5 months; 95% CI, 136.6–NR months; P < 0.01) and median PFS (32.3 months; 95% CI, 25.5–38.3 months versus 69.8 months; 95% CI, 56.8–91.5 months; P < 0.01). e, f OS and PFS for patients younger than 65 years when first-line treatment was commenced, with or without upfront SCT as consolidation. SCT was associated with a statistically significant difference in PFS (median PFS: 86.2 months; 95% CI, 65.4–147.0 months versus 40.0 months; 95% CI, 21.6–56.8 months; P < 0.01), and a trend towards improvement in OS (median OS: 165.0 months; 95% CI, 151.0–NR months versus 120.0 months; 95% CI, 101.0–NR months; P = 0.06)

Back to article page